Jefferies Group LLC Beam Therapeutics Inc. Transaction History

Jefferies Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 21, 2023	BUY	$29.86 - $62.36 $138,102 - $288,415	4,625 Added 108.26%	8,897 $344,000
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $519,593 - $1.09 Million	17,401 New	17,401 $366,000
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $273,920 - $549,849	-4,272 Closed	0 $0
Q1 2021 Sep 21, 2023	BUY	$71.28 - $120.75 $304,508 - $515,844	4,272 New	4,272 $341,000
Q1 2021 May 14, 2021	BUY	$71.28 - $120.75 $304,508 - $515,844	4,272 New	4,272 $342,000

234

75.6M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.8B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.